RIVANNA announces FDA clearance of Accuro 3S Needle Guide Kit
The Accuro 3S Needle Guide Kit, designed for use with the Accuro 3S ultrasound imaging system and Dual-Array™ transducer, includes single-use, sterile components that support infection control and promote workflow efficiency. The sterile patient drape is equipped with stabilization bands that secure the transducer for hands-free support during needle approach, facilitating a streamlined, single-operator workflow. This configuration allows clinicians to maintain both hands on the needle for tactile feedback. The Dual-Array transducer supports midline placement through the probe's central aperture, while the integrated probe cover isolates the needle insertion site from contaminants to help maintain a controlled procedural field.
"The FDA clearance of the Accuro 3S Needle Guide Kit underscores our commitment to providing clinicians with intuitive, workflow-enhancing tools that enhance procedural accuracy and patient safety," said
The Accuro 3S Needle Guide Kit reflects RIVANNA's commitment to advancing ultrasound-guided needle placement through innovative, user-friendly design, with safety and performance confirmed through comprehensive testing in accordance with FDA requirements.
About RIVANNA
RIVANNA is a commercial-stage medical device innovator and manufacturer based in
View original content to download multimedia:https://www.prnewswire.com/news-releases/rivanna-announces-fda-clearance-of-accuro-3s-needle-guide-kit-302643819.html
SOURCE RIVANNA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in July
- Bridenformal Launches Its 2027 Wedding Dress Collection in Mexico
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share